Which drug class does Firmagon belong to?

Firmagon, known generically as degarelix, is classified as a LHRH antagonist (luteinizing hormone-releasing hormone antagonist). This class of drugs works by directly inhibiting the action of GnRH on the pituitary gland, leading to reduced secretion of luteinizing hormone (LH) and follicle-stimulating hormone (FSH). This results in a rapid decrease in testosterone production in men, making it particularly effective in treating conditions like advanced prostate cancer.

By blocking GnRH receptors, LHRH antagonists like Firmagon provide a quick onset of action compared to GnRH agonists, which initially cause a surge in hormone levels before suppressing them. This characteristic makes LHRH antagonists preferable in scenarios where immediate hormonal control is necessary, such as in patients with advanced disease who may experience rapid progression.

Understanding the distinctions between LHRH antagonists and other classes, such as GnRH agonists, CDK inhibitors, and antiandrogens, is crucial in pharmacology and therapeutic decision-making. Each class has unique mechanisms and indications, reinforcing the importance of accurate classification and application in patient care.